Australia vaccine funding, Sinopharm’s global push, ECB accelerates stimulus

Canberra is contemplating investing in a A$1bn biopharmaceutical plant to reduce its dependence on imports of critical medicines, China’s state-backed pharmaceutical group, Sinopharm, wants more governments to buy its Covid-19 vaccine, and Spain is set to become the first EU country to amend its laws to give some gig economy workers employee rights. Plus, the FT’s markets editor, Katie Martin, explains why the European Central Bank will accelerate its bond buying programme. Australia considers funding vaccine maker to curb reliance on importshttps://www.ft.com/content/483e6275-6d27-433c-9cbc-6918f2c916c6?edit=trueSpain to grant gig delivery workers employee rightshttps://www.ft.com/content/73be294b-a43d-4387-aced-7b5cb0d91007?Sinopharm faces battle to turn Covid vaccine into a global successhttps://www.ft.com/content/99c7a9de-fc11-45ab-890b-f6733ccb4186ECB pledges to step up pace of stimulus to counter market sell-offhttps://www.ft.com/content/bd7ccf1d-3b07-4f13-9a14-68692ef84e95Rise of the retail army: the amateur traders transforming marketshttps://www.ft.com/content/7a91e3ea-b9ec-4611-9a03-a8dd3b8bddb5 Hosted on Acast. See acast.com/privacy for more information.